Dashboard
Manage Tickers

GERN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-maintains-buy-on-geron-lowers-price-target-to-4
Needham Maintains Buy on Geron, Lowers Pri...
11/05/2025 17:23:03

Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $5 to $4.

geron-expects-2025-operating-expenses-will-be-between-250m-and-260m-vs-approximately-270m-285m-prior
Geron Expects 2025 Operating Expenses Will...
11/05/2025 12:12:01

2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be between $250 million and $260...

geron-q3-eps-003-inline-sales-47227m-miss-52881m-estimate
Geron Q3 EPS $(0.03), Inline, Sales $47.22...
11/05/2025 12:10:06

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

geron-earnings-preview
Geron Earnings Preview
11/04/2025 19:09:14

geron-to-present-new-rytelo-data-on-lr-mds-and-myelofibrosis-at-ash-2025
Geron To Present New RYTELO Data On LR-MDS...
11/03/2025 14:11:53

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-...

gerons-coo-andrew-grethlein-to-depart-on-october-15-2025
Geron's COO Andrew Grethlein To Depart On ...
10/13/2025 20:42:13

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical co...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

geron-appoints-harout-semerjian-as-president-and-ceo-effective-tomorrow-succeeding-dawn-carter-bir-to-accelerate-rytelo-commercialization-and-phase-3-impactmf-trial
Geron Appoints Harout Semerjian As Preside...
08/06/2025 11:31:34

geron-q2-eps-002-beats-003-estimate-sales-49036m-beat-47281m-estimate
Geron Q2 EPS $(0.02) Beats $(0.03) Estimat...
08/06/2025 11:03:36

Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.3...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

goldman-sachs-reinstates-sell-on-geron-announces-1-price-target
Goldman Sachs Reinstates Sell on Geron, An...
07/10/2025 13:04:42

Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1 price target.

goldman-sachs-initiates-coverage-on-geron-with-sell-rating-announces-price-target-of-1
Goldman Sachs Initiates Coverage On Geron ...
07/10/2025 12:52:39

Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell rating and announces Price Targe...

geron-highlights-new-imerge-post-hoc-analyses-demonstrating-rytelos-clinical-benefit-in-lower-risk-mds-patients-across-key-subgroups-alongside-quality-of-life-and-transfusion-independence-data-at-asco-and-eha-2025
Geron Highlights New IMerge Post-Hoc Analy...
05/28/2025 12:40:50

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic s...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/07/2025 12:09:25

geron-q1-eps-003-beats-004-estimate-sales-3960m-miss-4822m-estimate
Geron Q1 EPS $(0.03) Beats $(0.04) Estimat...
05/07/2025 11:01:01

Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 p...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
03/21/2025 17:35:16

needham-reiterates-buy-on-geron-maintains-5-price-target
Needham Reiterates Buy on Geron, Maintains...
03/12/2025 11:24:06

Needham analyst Gil Blum reiterates Geron (NASDAQ:GERN) with a Buy and maintains $5 price target.

hc-wainwright--co-reiterates-neutral-on-geronto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/12/2025 11:17:28

HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) from Neutral to Neutral.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION